Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Amgen's Blincyto Adds Pediatric Claim For Leukemia

Executive Summary

Study supporting accelerated approval for the leukemia drug satisfied an FDA written request under the Best Pharmaceuticals for Children Act.

Advertisement

Related Content

Amgen's Cancer Strategy: A Multitude Of Modalities In Immuno-Oncology And Beyond
Keeping Track: Sandoz Erelzi Is Third Biosimilar To Clear FDA; Expanded Labels For Arzerra, Blincyto
Pediatric Study Requirements For Cancer Have FDA Support, But Pose Industry Challenges
Amgen’s Breakthrough Blincyto Clears FDA At Breakneck Pace, But With REMS Attached

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS119054

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel